Innovative Biosystems Inc. aims to become the premier global provider of affordable, convenient, and easy to use point-of-care testing solutions.
IBI will capitalize on the large market potential of the human POCT market (approximately $15 billion worldwide) and veterinary market (approximately $1 billion) with key offerings like the EZ-INR, MAX-Mini, and other supporting POCT products.
By cooperating with pre-existing distributors and medical suppliers around the globe, IBI will tap into key user demographics for both the human POCT and veterinary markets.
Recent News & Events
• AACC 2014, Chicago, IL: Come visit us at Booth #2343 and see the newest developments from IBI!
• The EZ-INR Coagulation Test Device is now CE Marked!